The invention relates to a method for the in vitro measurement of fibrin clot degradation on the basis of a curve of the lysis of a fibrin clot over time in a blood or plasma sample previously obtained from a patient who may have a deficiency in at least one coagulation factor, said method including determining a basal level value for the fibrin clot at a time t1, and determining a degraded level value for the fibrin clot at a subsequent time t2. The method may comprise an additional step of classifying the tested sample into a group reflecting a lysis profile of a fibrin clot. The invention also relates to a method for monitoring a therapeutic treatment administered to a patient who may have or who does have a deficiency in at least one coagulation factor, said method likewise further comprising a step of adjusting the therapeutic treatment followed by said patient, according to the classification obtained. The invention further relates to the use of an antifibrinolytic agent, in particular tranexamic acid (TXA) or a composition comprising said acid, for use in a therapeutic treatment, said use comprising the carrying out of a method according to invention, and means for implementing the invention.